PIK3CA mutations in vascular malformations by Castillo, Sandra D. et al.
Current Opinion in Hematology
 




Full Title:  PIK3CA Mutations in Vascular Malformations
Article Type: Review Article
Corresponding Author: Mariona Graupera, PhD






First Author: Sandra D. Castillo, PhD
First Author Secondary Information:
Order of Authors: Sandra D. Castillo, PhD
Eulalia Baselga, MD PhD
Mariona Graupera, PhD
Order of Authors Secondary Information:
Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation




PIK3CA Mutations in Vascular Malformations 
 
Sandra D. Castillo1,*, Eulalia Baselga2 and Mariona Graupera1,3,* 
 
1Vascular Signalling Laboratory, Program Against Cancer Therapeutic Resistance (ProCURE), Institut 
d´Investigació Biomèdica de Bellvitge (IDIBELL), Avinguda Gran Via 199-203, 08908 L´Hospitalet de Llobregat, 
Barcelona, Spain. 2Hospital de la Santa Creu i Sant Pau, Carrer de Sant Quintí 89, 08041 Barcelona, Spain. 
3CIBERONC, Instituto de Salud Carlos III, Madrid, Spain. 
 




Purpose of the review: Recently, it has been discovered that a subset of vascular malformations, of the 
lymphatic and venous type, are caused by oncogenic mutations in the PIK3CA gene. Now, efforts have been 
focused in the understanding of the molecular and cellular consequences of these mutations and the 
opportunities for novel targeted therapies for these diseases. 
Recent findings: Here, we review the latest findings in the biology of oncogenic PIK3CA mutations in the 
pathogenesis of vascular malformations. We focus on the recent development of in vitro and in vivo tools for 
the study of PIK3CA-mutant vascular malformations with special interest in preclinical models for drug testing. 
Also, we review the latest advances in PI3K inhibitors in the clinic and their repurposing for the treatment of 
lymphatic malformations (LMs) and venous malformations (VMs). 
Summary: Oncogenic mutations on PIK3CA causing LMs and VMs are also frequently found in epithelial cancer. 
Thus, fundamental research done in the cancer field during the past decades might be applied to the 
understanding of LMs and VMs. Likewise, repurposing PI3K pathway inhibitors that are currently in cancer 
clinical trials can be used as a novel strategy for the treatment of these diseases. Here, we also open a debate 
for the consideration of LMs and VMs as developmental tumours. 
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Vascular malformations are a heterogeneous group of diseases affecting a large population (1 in 100 
individuals) (1) for whom limited treatment options exist. These lesions appear during embryonic development 
and are manifested at birth (congenital) or throughout the life of affected individuals (2). Vascular 
malformations are classified according to their histological appearance in different categories that include low-
flow lesions: capillary, venous, and lymphatic; and fast-flow arteriovenous malformations. Specifically, venous 
malformations (VMs) are localized collections of abnormal and tortuous venous channels. VMs have a major 
impact on the quality of life of patients; they are painful and disfiguring, and many lead to bleeding, recurrent 
infections, thrombosis, organ dysfunction, and even death. Similarly, lymphatic malformations (LMs) are 
congenital lesions occurring as a result of a defect in the development of the lymphatic system. These lesions 
are composed by dilated lymphatic channels and can occur anywhere in the body (3). VMs and LMs do not 
regress but expand proportionally with the growth of the child. Current standard of care includes compression, 
surgical excision, and/or sclerotherapy (4). However, these treatment strategies are likely to be insufficient 
and patients commonly experience a high risk of recurrence and progression. In both types of malformations, 
the blood and lymphatic vessels are dedifferentiated, immature, and most likely occur as a consequence of an 
abnormal hyperproliferation of endothelial cells during development.  
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With the emergence of high-throughput and ultra-deep sequencing technologies, the genetic 
landscape of vascular malformations has undergone a great progress. A decade ago, it was determined that 
around half of sporadic VMs are caused by somatic gain-of-function mutations in the TEK gene which codes 
for the endothelial tyrosine-protein kinase receptor TIE-2 (5). In 2015 it was discovered that most LMs were 
caused by somatic oncogenic mutations in the PIK3CA gene (coding for the p110α isoform of PI3K lipid kinases) 
(6), and, a year later, it was demonstrated that around 25-30% of VMs are also caused by these oncogenic 
PIK3CA mutations (7) (8, 9)*. In most VMs, PIK3CA and TEK mutations are mutually exclusive, all triggering an 
overactivation of the PI3K signalling pathway. An unusual case has been recently reported in which both 
PIK3CA and TEK mutations have been found in endothelial cells derived from same VMs (10)**. Of note, in this 
specific case, neither PIK3CA nor TEK mutations are hotspots mutations of the disease.   
Despite the discovery of the genetic cause of venous and lymphatic malformations, it is still unclear 
how these mutations change the cellular phenotype and how the molecular mechanisms driven by these 
mutations lead to the pathogenesis of these diseases. Here, we review the most recent advances in the 
biological effects of PIK3CA mutations in VM and LM pathogenesis towards the implementation of new 
targeted therapies for these diseases. Also, we propose LMs and VMs to be considered as developmental 
tumours considering their genetics and biology. 
 
PIK3CA signalling in vascular biology  
PIK3CA encodes for the p110lipid kinase protein, one of the four p110 catalytic subunits of the class 
I phosphoinositide 3-kinases (PI3Ks) (11). In cells, p110 isoforms exist in a heterodimeric complex with a 
regulatory subunit. Based on the regulatory subunit binding preferences, they are grouped in class IA (p110, 
 and ) and class IB (p110). Class IA isoforms bind to a p85 regulatory subunit (there are five variants: p85α, 
p55α, p50α, p85β, and p55γ), while class IB isoform binds either to p84 or p101 regulatory subunits. The 
regulatory subunits prevent from p110s protein degradation, but also, the p85 subunits keep p110,  and  
in an inactive cytosolic state. Activation of class IA PI3Ks can occur by 3 modes, all of which start with binding 
of a ligand to receptor tyrosine kinases (RTKs). First mode of activation occurs through a direct binding of p85 
to RTKs allowing conformation change and activation of the p110 subunits. Another way of activation occurs 
through adaptor proteins such as the GRB2/GAB complex which bind p85 upon being recruited to RTKs. Finally, 
the small GTPases may also activate class I PI3Ks by interacting with the so called RAS binding domain (RBD) 
contained in the p110catalytic subunitsAdditionally,the p110 subunits can be activated by G protein-
coupled receptors (12).  
Class I PI3Ks activation generates the lipid phosphatidlylinositiol-3,4,5-triphosphate [PI(3,4,5)P3 or 
PIP3], which may be metabolised to PI(3,4)P2 by 5-phosphatases such as SHIP. Both, PI(3,4,5)P3 and PI(3,4)P2 
act as second messengers by interacting with lipid-binding pleckstrin homology (PH) domains in a variety of 
protein effectors and regulating their localization and/or activity. The main PI3K effector proteins include 
protein kinases (being the serine/threonine kinase AKT the most well-known), regulators of GTPases and 
scaffolding proteins (13). This plethora of downstream mediators allows PI3Ks to regulate cell growth, 
metabolism, survival and proliferation in physiology and disease (11, 13). The 3-phosphatase PTEN inhibits 
class I PI3K signalling by dephosphorylating PI(3,4,5)P3 and PI(3,4)P2. 
All class I PI3K isoforms produce the same lipid but they regulate distinct physiological functions. This 
is partially explained by their relative expression levels in different cell types and by their mode of activation 
by upstream signals (11). In agreement with the presence of activating mutations of PIK3CA in VMs and LMs, 
and not yet identified other mutant PI3K isoforms, p110 is the sole isoform required for blood and lymphatic 
vascular development (14-16). The catalytic domain of p110 has been reported to be necessary for 
angiogenesis and lymphangiogenesis (14, 15). In contrast, blocking the ability of p110 to bind RAS impairs 




lymphatic vascular development only (16). This indicates that p110 capacity to respond to upstream signals 
is different in blood and in lymphatic vessels’ endothelial cells.  Understanding how this occurs might shed light 
into the pathogenic mechanisms of PIK3CA mutations in VMs and LMs.  
An interesting observation from mouse gene targeting studies (including ubiquitous and endothelial 
cell-specific models) is that too much and too little activation of p110 leads to embryonic lethality due to 
incomplete development of blood vessels (9, 14, 17, 18). This suggests that endothelial cells are extremely 
sensitive to PIP3 fluctuations, and that its levels need to be tightly regulated for an adequate formation of the 
vascular plexus. This might also explain why activating mutations in PIK3CA have only been identified 
somatically and in a mosaic fashion as the presence of activating mutations in the germline is incompatible 
with life (Figure 1). From a biological perspective, the study of loss-of-function genetic models have unravelled 
that p110 signalling critically regulates collective cell migration during angiogenesis. Specifically, p110 
signalling prevents NUAK1-dependent phosphorylation of the myosin phosphatase targeting-1 (MYPT1) 
protein. This allows myosin light chain phosphatase (MLCP) activity which reduces actomyosin contractility 
(19)*. It remains to be unravelled whether these biological processes are also relevant in the pathogenic 
endothelium upon expression of activating mutations of PIK3CA. In line with this, defective cell migration cause 
capillary-venous malformations when endothelial cells are unable to re-distribute within the vascular network 
(20). Taken together, it is tempting to speculate that aberrant endothelial cell migration also accounts for the 
pathogenic mechanism induced by activating mutations in PIK3CA in LMs and VMs.  
 
Oncogenic PIK3CA mutations in LMs and VMs 
PIK3CA mutations occur in most LMs patients (21)* whereas PIK3CA-mutations in VMs are less 
common, being present in 25-30% of the cases (7-9). These discoveries are in line with previous and 
consequent findings of oncogenic PIK3CA mutations in the so-called PROS (PIK3CA-Related Overgrowth 
Spectrum) which also present vascular malformations (22). This suggests that PIK3CA mutations appear at 
different stages during embryonic development affecting different cell types and in a mosaic fashion which 
leads to the broad spectrum of syndromes caused by these mutations (23). Since isolated LMs and VMs are 
usually localized lesions, it is tempting to speculate that, in these cases, mutations occur late during 
development, affecting a single clone of endothelial cells (Figure 1). However, the cell of origin of these 
malformations is still a mystery; whether they come from an endothelial cell progenitor or an already 
venous/lymphatic-committed endothelial cell remains unknown. In fact, since lymphatic vessels arise from 
primitive lymph sacs within veins (24), LMs and VMs might arise from the same cell lineage at different 
embryonic stages. This is plausible since very often LMs and VMs are mixed malformations with the presence 
of abnormal lymphatic and blood vessels within the lesion. Furthermore, LMs appear filled with both lymphatic 
fluids and blood. This speculation highlights that single cell-tracing in vivo studies might be of the utmost 
importance to reveal the cellular origin of LMs and VMs and better understand their pathogenesis. 
Like in epithelial cancer, the most common mutations found in LMs and VMs are activating mutations 
in the helical (E542K, E542K) and kinase (H1047R, H1047L) domains of PIK3CA (25). In fact, these are the so-
called oncogenic mutations in PIK3CA. These two types of mutations lead to a constitutive binding of p110α to 
the plasma membrane by two different and independent gain-of-function mechanisms both of which trigger 
an overactivation of the PI3K signalling pathway (26, 27). It is still unclear whether helical or kinase mutations 
prevail one over the other in these pathologies. Other less studied activating mutations in PIK3CA have been 
also found in LMs and VMs (10, 21, 28) (29)**. To date, there is no well-known correlation between any 
particular PIK3CA mutation and phenotype. However, a recent study including data from sixteen institutions 
has given valuable information about the genetic landscape of vascular anomalies with broad phenotypic 




severity (29). A critical question is whether higher activation (helical and kinase mutations) leads to more 
aggressive phenotypes in LMs and VMs.  
 
Biology of PIK3CA mutations in LMs and VMs 
With the discovery of PIK3CA mutations in LMs and VMs, the next required step for fundamental 
researchers in the field is to understand their biological effect in the pathogenesis of these diseases. For this, 
there has been developed a wide spectrum of in vitro and in vivo models of LMs and VMs: from cell lines 
ectopically expressing the mutations to sophisticated genetic mouse models of the diseases (Table 1). By 
integrating these very recent studies we have gained an extensive molecular and cellular insight into the 
pathogenesis of LMs and VMs. Importantly, these studies have served as critical proof-of-concept for the use 
of targeted therapies in these diseases. However, these are still very early days for a comprehensive and deep 
understanding of the pathogenesis of LMs and VMs and many questions are still unanswered since their 
genetic cause was only recently discovered. Yet, great advances in the molecular and cellular processes 
underlying the pathogenesis of LMs and VMs have been made (Figure 2). Most of the fundamental and 
preclinical studies in LMs have been made using human LM-derived endothelial cells (6, 21, 28, 30-32). These 
works, apart from discovering PIK3CA oncogenic mutations in LMs, have demonstrated that PIK3CA-mutant 
lymphatic endothelial cells show enhanced proliferation and sprouting capacity. Also, in vitro preclinical 
studies reveal that PI3K pathway inhibitors effectively block PI3K pathway overactivation and proliferation. 
However, the inhibitors tested (mostly pan-PI3K and PI3K downstream pathway inhibitors) are not specifically 
targeting mutant cells since they also impaired cell growth in normal lymphatic endothelial cells. At the 
molecular level, these studies assess the expression of lymphangiogenic factors on PIK3CA-mutant cells. They 
show that VEGF-C, VEGFR3, and Neuropilin-2 are overexpressed in these cells, while Angiopoietin-2 (ANG-2) 
and CXCR4 are downregulated, leading to pro-angiogenic properties of these cells (6, 30). Even though these 
studies have much helped in the understanding of LM pathogenesis, yet, unbiased, high throughput molecular 
approaches will allow to decipher new key players in the generation and maintenance of LMs. Moreover, 
genetically-engineered animal models of this disease (such as mice or zebrafish) will strongly benefit the field 
by providing highly valuable preclinical tools to test potential molecular therapies for LMs. This will also 
generate crucial knowledge in its pathogenesis, such as deciphering the cell origin, mutant-cell dynamics or 
the involvement of other cell types. A very recent study has provided the first PIK3CA-driven mouse model of 
LMs (32). Although this mouse model resembles generalized lymphatic anomaly (GLA), where the LMs are 
diffuse or multifocal, it serves as a preclinical model of LMs. Indeed, the authors show clinical improvement in 
these mice when treated with the mTOR inhibitor rapamycin and this was further supported in a pilot clinical 
assay. Still, this model expresses the mutant form of Pik3ca under the Rosa26 locus which might lead to non-
physiological expression levels of Pik3ca. It is possible then that some of the biological effects occurring in 
these mice are caused by abnormal mutant Pik3ca overexpression; this might be overcome by using a mouse 
model expressing mutant Pik3ca under its endogenous promoter. 
Biological research on PIK3CA-driven VMs is a step further compared to LMs, probably due to the 
development of xenograft and genetic mouse models of this disease (8-10, 33). Critically, when the transgenic 
mouse model finely reproduces the aetiology of VMs (Pik3ca mutation expressed under its endogenous 
promoter in a mosaic fashion within the embryonic mesoderm) these lesions fully recapitulate the systemic 
effects occurring in humans with isolated VMs such as intravascular coagulopathy (high D-dimer levels) or 
phlebectasias of the main internal veins (8). This highlights the need to use accurate preclinical models in order 
to assess therapy efficacy. VM mouse models have further demonstrated the exceptional sensitivity of 
endothelial cells for Pik3ca alterations since ubiquitous and non-endothelial specific expression of mutant 
Pik3ca leads to the development of VMs. The cellular phenotype triggered by oncogenic PIK3CA mutations in 




VMs is similar to LMs, where endothelial cells show enhanced proliferation (8-10, 33). Also, Pik3ca-driven VMs 
in mice show scarce mural cell coverage, a feature typically observed in human VMs (8). At the molecular level, 
targeted approaches have shown that PDGFB and ANG-2 expression is reduced in PIK3CA mutant endothelial 
cells, which could contribute to the poor mural cell coverage in these lesions (8, 9). Arteriovenous specification 
markers are also reduced in these mutant cells, supporting the idea of a dedifferentiated or progenitor-like 
state of these cells. In vivo preclinical studies for VMs have demonstrated that rapamycin and the p110α-
specific inhibitor BYL719 are effective in reducing VM lesions as well as limiting the systemic effects of these 
malformations (8, 9). These drugs reduce PIK3CA-mutant endothelial cell proliferation; however, for already-
established VMs which are low proliferative the mechanism of action of these inhibitors in still unclear.  
 
Are LMs and VMs developmental tumours? 
LMs and VMs are a collection of abnormal and non-functional vascular channels in which the vascular 
vessels are dedifferentiated and immature, and they lack mural cell coverage. LMs and VMs have long been 
considered “vascular malformations” but not “vascular tumours”.  This is partially based on the observation 
that in adults these vascular malformations are relatively static (34, 35); hence these lesions are considered 
slow proliferative malformations. This is compatible with the fact that the vasculature primarily expands during 
embryonic development and remains quiescent in adulthood. Furthermore, it suggests that the presence of 
the mutation in only endothelial cells is not sufficient to result in high proliferative vascular lesions, and thereby 
growth factor signals are required to promote proliferation. In line with this, endothelial cell hyperproliferation 
during vasculogenesis has previously been shown to give rise to vessel hyperfusion and to result in dilated, 
dysfunctional vessels, similar to those found in VMs (36). Yet, it should be taken into consideration that PIK3CA-
driven LMs and VMs do share most of the typical characteristics of the so-called childhood solid tumours or 
developmental solid tumours (37, 38). LMs and VMs are rare congenital entities: they arise as a consequence 
of genetic errors during development. The cell of origin of LMs and VMs is mesodermal, as mainly occurs in 
paediatric tumours. In paediatric tumours, often, a single, specific driver alteration might promote cancer 
development in certain cell lineages during a crucial developmental period. In LMs and VMs, a single PIK3CA 
activating mutation is sufficient to develop the lesion when affecting endothelial cells, a cell type that has been 
proven to be extremely sensitive to PIK3CA alterations. In addition, the same PIK3CA mutations occurring in 
LMs and VMs are frequently found in adult epithelial tumours such as breast or colon (13). However, in contrast 
to LMs and VMs, epithelial adult tumours bearing PIK3CA mutations need a multiple-hit process in which 
genetic alterations accumulate before the onset of the tumour. The current paradigm posits that LMs and VMs 
do not metastasize which fits with the fact that most of these malformations are presented as isolated lesions. 
However, occasionally there are patients in which the disease is manifested as multifocal. This has been 
described for VMs carrying mutations in the TEK gene (39), an upstream activator of p110, and for GLA 
carrying mutations in PIK3CA (32). Yet, it is not known whether these multifocal lesions within the patient have 
arisen from the same early precursor or the lesions derive from others through dissemination or metastasis. 
Although the current studies provide valuable insights, much work on clonal evolution is still required to 
complete this picture. With these premises, the current classification of LMs and VMs calls for a debate.  
 
Future perspectives and therapeutic opportunities 
The discovery of oncogenic PIK3CA mutations as drivers of LMs and VMs has opened an enormous 
window of opportunities for the fundamental understanding of the pathogenesis of these malformations as 
well as of the role of this key gene in the disease. There is no doubt that this has also had an invaluable impact 
on the way these patients are managed; from diagnostic approaches to therapeutic opportunities. In order to 
optimize efforts in the path to discover new molecular players and cellular processes driven by PIK3CA 




mutations in LMs and VMs, we advise to always keep in mind the “oncogenic” nature of these mutations. 
Indeed, most of the functional research done so far has been focused on assessing the proliferative and growth 
capacity of mutant cells. In line with this, findings made in the cellular and molecular mechanisms driven by 
oncogenic PIK3CA mutations in a cancer context might be applied to understand the pathogenesis of these 
vascular malformations. For instance, it has been shown that oncogenic PIK3CA leads to centrosome 
amplification and tolerance to spontaneous genome doubling, which might account for irreversible genetic 
changes in tumours with these mutations (18). Another example of the biological impact of these mutations 
in epithelial cancer is the switch on cellular metabolic requirements (40). Might these mechanisms be also 
applied to PIK3CA-driven LMs and VMs? Also, the experimental approaches to assess the molecular 
mechanisms triggered by PIK3CA mutations in LMs and VMs have been mostly biased, based in the canonical 
PI3K signalling pathway where activation of AKT is at the core of the pathway. Therefore, a holistic approach 
using a combination of high throughput technologies will be very valuable to decipher new molecular players 
involved in the pathogenesis of these diseases. This will impact in the development of novel therapies in 
combination with PI3K inhibitors. 
At present, LMs and VMs are often treated with rapamycin or rapamycin analogues such as everolimus 
or sirolimus with success in the improvement of lesions and quality of life of patients (41). However, these 
malformations do not significantly regress or disappear upon rapamycin treatment (41). The use of p110α-
specific inhibitors, which are currently on clinical trials for cancer (42, 43), might be a better option for LMs 
and VMs caused by PIK3CA mutations. Still these inhibitors are currently used at maximum-tolerated doses in 
cancer patients making these drugs poorly tolerated by the patients. Also, when used at high concentrations, 
they induce signalling feedback loops that can block their effect. A recent successful study treating PROS 
patients with the p110α-specific inhibitor BYL719 has given new hope for VMs and LMs patients (44)**. Thus, 
long-term treatment with low-dose of p110α inhibitor could normalize aberrant PI3K signalling avoiding 
systemic toxicity and be effective in reducing or eliminating PIK3CA-driven vascular malformations. The 
efficacy of these drugs at low doses is crucial taking into account that these are congenital diseases and most 
patients are paediatric. Similar to developmental tumours, LMs and VMs carrying a single mutation might be 
much more sensitive to targeted therapies than adult tumours which carry multiple genetic alterations (37). It 
is also important to keep in mind that new fundamental insight in the pathogenesis of LMs and VMs may lead 




 Since the discovery of PIK3CA mutations in LMs and VMs, not other genetic alteration has been found 
in these diseases. Yet, the genetic causes of all LMs and VMs cases have not been identified; thus, the discovery 
of new genetic events in these diseases will be crucial to apply targeted therapies. In line with this, the 
comprehensive genetic landscape of LMs and VMs will lead to an accurate stratification of these patients. 
Likewise, unbiased molecular approaches might shed light on unexpected roles of PIK3CA mutations in the 
pathogenesis of these vascular malformations which might lead to the development of novel therapeutic 
strategies. Lastly, we open a debate for the consideration of LMs and VMs as developmental tumours; this 
might have a positive impact in the clinical management of these diseases. 
 
Key points 
- Oncogenic PIK3CA mutations cause venous and lymphatic vascular malformations. 
- PIK3CA mutations lead to a hyperproliferative phenotype of endothelial cells, probably as the main 
mechanisms for the pathogenesis of venous and lymphatic vascular malformations. 




- PIK3CA-mutant vascular malformations present similar characteristics to developmental tumours. 
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Figure titles and legends 
 
Table 1. Experimental in vitro and in vivo models of PIK3CA-driven LMs and VMs. 
Figure 1. Effect of germline and somatic PIK3CA mutations during embryonic development and adulthood. 
Figure 2. Molecular and cellular mechanisms driven by PIK3CA mutations in the pathogenesis of LMs and VMs. 
 
 
Table 1. Experimental in vitro and in vivo models of PIK3CA-driven LMs and VMs. 
Disease Model Molecular mechanism 
Organismal phenotype 
and cellular mechanism 
Ref. 
LM Lymphatic endothelial cells from human LMs. 
Upregulation of VEGFR3 and 
Neuropilin-2. 
Increased cell proliferation. (6) 
LM Lymphatic endothelial cells from human LMs. 
Upregulation of VEGF-C and 
COX2. Downregulation of ANG-2 
and CXCR4. 




Mouse model of adult LM-GLA: lymphatic endothelial 
cell expression of mutant Pik3ca. 
na 
Hyperplastic lymphatic network. 
Functional impairment of lymphatic 
vessels. Increased cell proliferation.  
(32) 
VM HUVECs with ectopic expression of mutant PIK3CA. 
Downregulation of ANG-2 and 
PDGFB. 
Abnormal morphology of endothelial 
cells. Loss of ECM fibronectin. 
(7) 
VM 
Mouse model of congenital VMs: mosaic expression of 
mutant Pik3ca in the embryonic mesoderm under its 
endogenous promoter. 
Mouse model of endothelial-specific expression of 
mutant Pik3ca (postnatal retinas). 
Downregulation of Pdfgb and 
arteriovenous specification 
markers. 
Congenital VMs (cutaneous and 
internal). Systemic effects: 
phlebectasia of internal veins, 
bleedings. 
Endothelial cell hyperproliferation; 
loss of mural cell coverage.  
(8) 
VM 
Mouse model of adult VMs: ubiquitous expression of 
mutant Pik3ca. 
HUVECs with ectopic expression of mutant PIK3CA. 
Downregulation of ANG-2. 
Adult VMs (cutaneous and internal). 
Systemic effects: increased D-dimer 
levels. 
Endothelial cell hyperproliferation. 
Aberrant tube formation.  
(9) 
VM 
Patient-derived VM-endothelial cell mouse xenograft 
model. 
na Scarce mural cell coverage. (10) 
VM 
Mouse model of VMs: endothelial-specific expression 
of mutant Pik3ca. 
HUVECs with ectopic expression of mutant PIK3CA. 
na 
Adult internal VMs. Recruitment of 
inflammatory cells to the VM. 
Increased cell proliferation and 
senescence. Enhanced angiogenic 
sprouting. 
(33) 
LMs: lymphatic malformations; VMs: venous malformations; GLA: generalized lymphatic anomaly; HUVECs: human umbilical vein endothelial cells. Na: not 
applicable. 
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